Bae Bong Kyung, Kim Jae-Chul
Department of Radiation Oncology, Kyungpook National University School of Medicine, Daegu, Korea.
Radiat Oncol J. 2016 Sep;34(3):168-176. doi: 10.3857/roj.2016.01669. Epub 2016 Aug 22.
The purpose of current study is to evaluate the response of the patients with portal vein thrombosis (PVT) or hepatic vein thrombosis (HVT) in hepatocellular carcinoma (HCC) treated with three-dimensional conformal radiation therapy (3D-CRT). In addition, survival of patients and potential prognostic factors of the survival was evaluated.
Forty-seven patients with PVT or HVT in HCC, referred to our department for radiotherapy, were retrospectively reviewed. For 3D-CRT plans, a gross tumor volume (GTV) was defined as a hypodense filling defect area in the portal vein (PV) or hepatic vein (HV). Survival of patients, and response to radiation therapy (RT) were analyzed. Potential prognostic factors for survival and response to RT were evaluated.
The median survival time of 47 patients was 8 months, with 1-year survival rate of 15% and response rate of 40%. Changes in Child-Pugh score, response to RT, Eastern cooperative oncology group performance status (ECOG PS), hepatitis C antibody (HCVAb) positivity, and additional post RT treatment were statistically significant prognostic factors for survival in univariate analysis (p = 0.000, p = 0.018, p = 0.000, p = 0.013, and p = 0.047, respectively). Of these factors, changes in Child-Pugh score, and response to RT were significant for patients' prognosis in multivariate analysis (p = 0.001 and p = 0.035, respectively).
RT could constitute a reasonable treatment option for patients with PVT or HVT in HCC with acceptable toxicity. Changes in Child-Pugh score, and response to RT were statistically significant factors of survival of patients.
本研究旨在评估三维适形放疗(3D-CRT)治疗肝细胞癌(HCC)合并门静脉血栓形成(PVT)或肝静脉血栓形成(HVT)患者的疗效。此外,还评估了患者的生存率及生存的潜在预后因素。
回顾性分析47例因HCC合并PVT或HVT转诊至我科接受放疗的患者。对于3D-CRT计划,大体肿瘤体积(GTV)定义为门静脉(PV)或肝静脉(HV)内的低密度充盈缺损区。分析患者的生存率及放疗反应。评估生存及放疗反应的潜在预后因素。
47例患者的中位生存时间为8个月,1年生存率为15%,缓解率为40%。在单因素分析中,Child-Pugh评分变化、放疗反应、东部肿瘤协作组体能状态(ECOG PS)、丙型肝炎抗体(HCVAb)阳性及放疗后额外治疗是生存的统计学显著预后因素(分别为p = 0.000、p = 0.018、p = 0.000、p = 0.013和p = 0.047)。在这些因素中,Child-Pugh评分变化及放疗反应在多因素分析中对患者预后具有显著意义(分别为p = 0.001和p = 0.035)。
放疗对于HCC合并PVT或HVT患者可构成毒性可接受的合理治疗选择。Child-Pugh评分变化及放疗反应是患者生存的统计学显著因素。